{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T10:12:56Z","timestamp":1766139176872,"version":"3.44.0"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T00:00:00Z","timestamp":1748649600000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009123","name":"Norwegian University of Science and Technology","doi-asserted-by":"publisher","award":["70442762"],"award-info":[{"award-number":["70442762"]}],"id":[{"id":"10.13039\/100009123","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Deletion in 22q and mutations in the neurofibromatosis type 2 (NF2) gene are frequent in sporadic meningiomas. The tumor suppressor protein merlin is encoded by NF2, and mutations may promote tumor development. NF2 status is increasingly important in meningioma diagnostics and we questioned whether merlin immunohistochemistry could be used as an accessible and affordable surrogate marker for prediction of NF2 mutations. Previous studies on merlin immunoreactivity have reported diverging results. We aimed to describe the immunohistochemical expression of merlin in a large series of meningiomas and relate these findings to clinicopathological features and NF2 status. Standardized immunohistochemistry was conducted on 172 meningiomas using three different merlin antibodies directed toward the N-terminal, C-terminal and phospho-merlin (ser 518). Twenty of the included cases had known NF2 status. All tumor specimens were immunoreactive for the three merlin antibodies. The immunoreactivity of phosphorylated merlin was higher in meningothelial tumors. There were no other significant associations between merlin immunoreactivity and NF2 status, WHO grade, tumor subtype, tumor location or gender. These results indicate that merlin immunoreactivity does not seem to be predictive of NF2 mutation, as merlin was abundantly expressed by all included tumors and independently of NF2 status.<\/jats:p>","DOI":"10.1093\/jnen\/nlaf058","type":"journal-article","created":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T20:02:16Z","timestamp":1748635336000},"page":"825-830","source":"Crossref","is-referenced-by-count":2,"title":["Merlin immunoreactivity fails to predict <i>neurofibromatosis type 2<\/i> mutations in human meningiomas"],"prefix":"10.1093","volume":"84","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9521-1032","authenticated-orcid":false,"given":"Sofie Eline","family":"Tollefsen","sequence":"first","affiliation":[{"name":"Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU) , Trondheim,","place":["Norway"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0567-7822","authenticated-orcid":false,"given":"Rahmina","family":"Meta","sequence":"additional","affiliation":[{"name":"Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU) , Trondheim,","place":["Norway"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5954-4817","authenticated-orcid":false,"given":"Ole","family":"Solheim","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, St Olavs Hospital, Trondheim University Hospital , Trondheim,","place":["Norway"]},{"name":"Department of Neuromedicine and Movement Science, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU) , Trondheim,","place":["Norway"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7678-994X","authenticated-orcid":false,"given":"Patricia","family":"Mj\u00f8nes","sequence":"additional","affiliation":[{"name":"Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU) , Trondheim,","place":["Norway"]},{"name":"Department of Pathology, St Olavs Hospital , Trondheim,","place":["Norway"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9977-5935","authenticated-orcid":false,"given":"Ingfrid","family":"Vestrheim","sequence":"additional","affiliation":[{"name":"Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU) , Trondheim,","place":["Norway"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenche","family":"Sjursen","sequence":"additional","affiliation":[{"name":"Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU) , Trondheim,","place":["Norway"]},{"name":"Department of Medical Genetics, St Olavs Hospital , Trondheim,","place":["Norway"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8345-6852","authenticated-orcid":false,"given":"Sverre Helge","family":"Torp","sequence":"additional","affiliation":[{"name":"Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU) , Trondheim,","place":["Norway"]},{"name":"Department of Pathology, St Olavs Hospital , Trondheim,","place":["Norway"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,5,30]]},"reference":[{"key":"2025082003514736200_nlaf058-B1","first-page":"283","volume-title":"Central Nervous System Tumours","author":"Sahm","year":"2021"},{"key":"2025082003514736200_nlaf058-B2","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol"},{"key":"2025082003514736200_nlaf058-B3","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1093\/neuonc\/noae170","article-title":"cIMPACT-NOW update 8: clarifications on molecular risk parameters and recommendations for WHO grading of meningiomas","volume":"27","author":"Sahm","year":"2025","journal-title":"Neuro Oncol"},{"key":"2025082003514736200_nlaf058-B4","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1097\/CCO.0000000000000687","article-title":"Molecular alterations in meningioma: prognostic and therapeutic perspectives","volume":"32","author":"Birzu","year":"2020","journal-title":"Curr Opin Oncol"},{"key":"2025082003514736200_nlaf058-B5","doi-asserted-by":"crossref","first-page":"988","DOI":"10.3390\/ijms19040988","article-title":"NF2\/merlin inactivation and potential therapeutic targets in mesothelioma","volume":"19","author":"Sato","year":"2018","journal-title":"Int J Mol Sci"},{"key":"2025082003514736200_nlaf058-B6","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.3390\/cancers11111633","article-title":"The role of merlin\/NF2 loss in meningioma biology","volume":"11","author":"Lee","year":"2019","journal-title":"Cancers (Basel)"},{"key":"2025082003514736200_nlaf058-B7","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/nrneurol.2017.168","article-title":"Advances in meningioma genetics: novel therapeutic opportunities","volume":"14","author":"Preusser","year":"2018","journal-title":"Nat Rev Neurol"},{"key":"2025082003514736200_nlaf058-B8","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1200\/JCO.21.02371","article-title":"Alliance A071401: phase II trial of focal adhesion kinase inhibition in meningiomas with somatic NF2 mutations","volume":"41","author":"Brastianos","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025082003514736200_nlaf058-B9","doi-asserted-by":"crossref","first-page":"e5125","DOI":"10.1590\/1414-431X20155125","article-title":"Expression of merlin, NDRG2, ERBB2, and c-MYC in meningiomas: relationship with tumor grade and recurrence","volume":"49","author":"Ongaratti","year":"2016","journal-title":"Braz J Med Biol Res"},{"key":"2025082003514736200_nlaf058-B10","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s004010050608","article-title":"Expression of neurofibromatosis 2 protein in human brain tumors: an immunohistochemical study","volume":"93","author":"Hitotsumatsu","year":"1997","journal-title":"Acta Neuropathol"},{"key":"2025082003514736200_nlaf058-B11","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/00005072-199704000-00007","article-title":"Immunohistochemical detection of schwannomin and neurofibromin in vestibular schwannomas, ependymomas and meningiomas","volume":"56","author":"Huynh","year":"1997","journal-title":"J Neuropathol Exp Neurol"},{"key":"2025082003514736200_nlaf058-B12","first-page":"5995","article-title":"Tight association of loss of merlin expression with loss of heterozygosity at chromosome 22q in sporadic meningiomas","volume":"59","author":"Ueki","year":"1999","journal-title":"Cancer Res"},{"key":"2025082003514736200_nlaf058-B13","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1093\/jnen\/59.10.872","article-title":"Merlin, DAL-1, and progesterone receptor expression in clinicopathologic subsets of meningioma: a correlative immunohistochemical study of 175 cases","volume":"59","author":"Perry","year":"2000","journal-title":"J Neuropathol Exp Neurol"},{"key":"2025082003514736200_nlaf058-B14","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/j.humpath.2007.01.027","article-title":"Evaluation of NF2 gene deletion in sporadic schwannomas, meningiomas, and ependymomas by chromogenic in situ hybridization","volume":"38","author":"Begnami","year":"2007","journal-title":"Hum Pathol"},{"key":"2025082003514736200_nlaf058-B15","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/PAI.0b013e318289f490","article-title":"The significance of immunohistochemical expression of merlin, Ki-67, and p53 in meningiomas","volume":"22","author":"Pavelin","year":"2014","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"2025082003514736200_nlaf058-B16","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/apm.12916","article-title":"Biomarkers in tumors of the Central nervous system\u2014a review","volume":"127","author":"Scheie","year":"2019","journal-title":"APMIS"},{"key":"2025082003514736200_nlaf058-B17","doi-asserted-by":"crossref","first-page":"e3140","DOI":"10.7717\/peerj.3140","article-title":"Expression and clinical value of EGFR in human meningiomas","volume":"5","author":"Arnli","year":"2017","journal-title":"PeerJ"},{"key":"2025082003514736200_nlaf058-B18","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.3390\/cancers13061262","article-title":"The prognostic value of methylation signatures and NF2 mutations in atypical meningiomas","volume":"13","author":"Meta","year":"2021","journal-title":"Cancers"},{"key":"2025082003514736200_nlaf058-B19","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1440-1789.2006.00737.x","article-title":"NF2 gene expression in sporadic meningiomas: relation to grades or histotypes real time-pCR study","volume":"27","author":"Buccoliero","year":"2007","journal-title":"Neuropathology"},{"key":"2025082003514736200_nlaf058-B20","doi-asserted-by":"crossref","first-page":"i4","DOI":"10.1093\/neuonc\/noy178","article-title":"Molecular and translational advances in meningiomas","volume":"21","author":"Suppiah","year":"2019","journal-title":"Neuro-Oncology"},{"key":"2025082003514736200_nlaf058-B21","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1093\/hmg\/7.3.335","article-title":"Defects in neurofibromatosis 2 protein function can arise at multiple levels","volume":"7","author":"Gutmann","year":"1998","journal-title":"Hum Mol Genet"},{"key":"2025082003514736200_nlaf058-B22","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1007\/BF02281874","article-title":"Screening for mutations in the neurofibromatosis type 2 (NF2) gene in sporadic meningiomas","volume":"97","author":"De Vitis","year":"1996","journal-title":"Hum Genet"},{"key":"2025082003514736200_nlaf058-B23","doi-asserted-by":"crossref","first-page":"3895","DOI":"10.1038\/s41467-022-31686-6","article-title":"Loss-of-function, gain-of-function and dominant-negative mutations have profoundly different effects on protein structure","volume":"13","author":"Gerasimavicius","year":"2022","journal-title":"Nat Commun"},{"key":"2025082003514736200_nlaf058-B24","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/onc.2015.125","article-title":"Role of merlin\/NF2 inactivation in tumor biology","volume":"35","author":"Petrilli","year":"2016","journal-title":"Oncogene"},{"key":"2025082003514736200_nlaf058-B25","doi-asserted-by":"crossref","first-page":"5704","DOI":"10.3390\/cancers13225704","article-title":"Somatostatin receptors in human meningiomas\u2014clinicopathological aspects","volume":"13","author":"Tollefsen","year":"2021","journal-title":"Cancers"},{"key":"2025082003514736200_nlaf058-B26","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00401-015-1459-3","article-title":"Somatostatin receptor 2a is a more sensitive diagnostic marker of meningioma than epithelial membrane antigen","volume":"130","author":"Menke","year":"2015","journal-title":"Acta Neuropathol"},{"key":"2025082003514736200_nlaf058-B27","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1093\/neuonc\/noab150","article-title":"EANO guideline on the diagnosis and management of meningiomas","volume":"23","author":"Goldbrunner","year":"2021","journal-title":"Neuro Oncol"},{"key":"2025082003514736200_nlaf058-B28","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.3389\/fonc.2019.01472","article-title":"Recent advances in meningioma immunogenetics","volume":"9","author":"Al-Rashed","year":"2019","journal-title":"Front Oncol"},{"key":"2025082003514736200_nlaf058-B29","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1093\/brain\/awm249","article-title":"Magic but treatable? Tumours due to loss of merlin","volume":"131","author":"Hanemann","year":"2008","journal-title":"Brain"},{"key":"2025082003514736200_nlaf058-B30","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/path.909","article-title":"NF2 status of meningiomas is associated with tumour localization and histology","volume":"194","author":"Kros","year":"2001","journal-title":"J Pathol"},{"key":"2025082003514736200_nlaf058-B31","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.molonc.2014.03.008","article-title":"Garbage in, garbage out: a critical evaluation of strategies used for validation of immunohistochemical biomarkers","volume":"8","author":"O\u2019Hurley","year":"2014","journal-title":"Mol Oncol"}],"container-title":["Journal of Neuropathology &amp; Experimental Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jnen\/article-pdf\/84\/9\/825\/63409350\/nlaf058.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnen\/article-pdf\/84\/9\/825\/63409350\/nlaf058.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T07:51:57Z","timestamp":1755676317000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jnen\/article\/84\/9\/825\/8154249"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,30]]},"references-count":31,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,5,30]]},"published-print":{"date-parts":[[2025,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jnen\/nlaf058","relation":{},"ISSN":["0022-3069","1554-6578"],"issn-type":[{"type":"print","value":"0022-3069"},{"type":"electronic","value":"1554-6578"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,5,30]]}}}